Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571060 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial in Adult Participants With Acute Migraines
A Phase 3 study of Migraine, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,978
- Enrollment target
- 20
- Study locations
NCT04571060: Completed Phase 3 study of Migraine, sponsored by Pfizer.
NCT04571060 is a Phase 3 study of Migraine that has completed, run by Pfizer. The registered enrollment target is 1,978 participants, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (483% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04571060, a Phase 3 study of Migraine, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,978 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
Primary Outcome
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zavegepant
Study Locations (20)
California
- Axiom Research, LLC - Colton
- Pharmacology Research Institute - Encino
- eStudySite - La Mesa
- Synergy San Diego - Lemon Grove
- Collaborative Neuroscience Network, LLC - Long Beach
- Pharmacology Research Institute - Los Alamitos
- Clinical Research Institute - Los Angeles
- Wr-Pri, Llc - Newport Beach
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- California Neuroscience Research Medical Group, Inc. - Sherman Oaks
Alabama
- Medical Affiliated Research Center - Huntsville
- Coastal Clinical Research, LLC, An AMR Co. - Mobile
Arizona
- MD First Research - Chandler
- Tucson Neuroscience Research - Tucson
Connecticut
- CT Clinical Research - Cromwell
- Ki Health Partners, LLC dba New England Institute for Clinical Research - Stamford
Florida
- Neurology Offices of South Florida - Boca Raton
- Clinical Neuroscience Solutions, Inc. - Jacksonville
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,978 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 3 |
What the finished NCT04571060 record still lists
NCT04571060 is an interventional study that assigns participants to a tested intervention. Its 1,978 participants enrollment target places it among the larger protocols in the corpus, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (483% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04571060 names 20 study sites across 6 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04571060 about?
NCT04571060 is a clinical study titled "Randomized Trial in Adult Participants With Acute Migraines". The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
What is the current status of trial NCT04571060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,978 participants. The study started on 2020-10-27. Estimated completion is 2021-10-22.
What conditions does trial NCT04571060 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT04571060?
The interventions under investigation include: Placebo (DRUG), Zavegepant (DRUG).
Who is sponsoring clinical trial NCT04571060?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04571060 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04571060's enrollment target sits among peer trials
1,978 3rd of 102 higher than 100 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI